Algeta Sees ’Widespread’ Interest in Thorium Cancer Technology

Algeta ASA, the Norwegian company partnered with Bayer AG for one of its experimental cancer treatments, has seen “widespread” interest in collaboration on a second, its thorium-227 technology, Chief Executive Officer Andrew Kay said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.